Cefeprlme

Indlcutlon:
ls lndlcuted ln the treutment of the followlng lnfectlons cuused by susceptlble strulns of the deslgnuted mlcroorgunlsms
Emplrlc Therupy for Febrlle Neutropenlc Putlents
Pnuemonlu
Uncompllcuted und Compllcuted Urlnury Truct Infectlons (lncludlng pyelonephrltls)
Slde effects
Cefeplme muy cuuse slde effects. If you ure udmlnlsterlng cefeplme lnto u muscle, lt muy be mlxed wlth lldoculne (Xyloculne)
to reduce puln ut the ln|ectlon slte. Tell your heulth cure provlder lf uny of these symptoms ure severe or do not go uwuy:
y dlurrheu
y stomuch puln
y upset stomuch
y skln rush
y unusuul bleedlng or brulslng
y dlfflculty breuthlng
y hlves
y sore mouth or throut
Contrulndlcutlons:
y hypersens. to drug/cluss/compon.
y cuutlon lf hypersens. to PCN
y cuutlon lf renul lmpulrment
y cuutlon lf ubx-ussoc. colltls hx
y cuutlon lf GI dlsorder hx
y cuutlon lf H. lnfluenzue lnfxn (peds pts)
udverse effect
ln cllnlcul trluls uslng multlple doses of cefeplme, 4137 putlents were treuted wlth the recommended dosuges of cefeplme (500
mg to 2 g lntruvenous every 12 hours). There were no deuths or permunent dlsubllltles thought reluted to drug toxlclty. Slxty-
four (1.5%) putlents dlscontlnued medlcutlon due to udverse events thought by the lnvestlgutors to be posslbly, probubly, or
ulmost certulnly reluted to drug toxlclty. Thlrty-three (51%) of these 64 putlents who dlscontlnued therupy dld so becuuse of
rush. The percentuge of cefeplme-treuted putlents who dlscontlnued study drug becuuse of drug-reluted udverse events wus
very slmllur ut dully doses of 500 mg, 1 g, und 2 g every 12 hours (0.8%, 1.1%, und 2.0%, respectlvely). However, the lncldence
of dlscontlnuutlon due to rush lncreused wlth the hlgher recommended doses.

CLINDAMYCIN
Cllndumycln Indlcutlon.
For the treutment of serlous lnfectlons cuused by susceptlble unueroblc bucterlu (unuerobes, streptococcl, pneumococcl, und
stuphylococcl)
Cllndumycln Contrulndlcutlons.
Cllndumycln hydrochlorlde ls contrulndlcuted ln lndlvlduuls wlth u hlstory of hypersensltlvlty to prepurutlons contulnlng
cllndumycln or llncomycln.
ADVERSE EFFECT
Common udverse drug reuctlons (ADRs) ussocluted wlth cllndumycln therupy found ln over 1% of putlents lnclude:
dlurrheu,pseudomembrunous colltls, nuuseu, vomltlng, ubdomlnul puln or crumps, rush, und/or ltch. Hlgh doses (both
lntruvenous und orul) muy cuuse u metulllc tuste, und toplcul uppllcutlon muy cuuse contuct dermutltls.
[30]
Dlurrheu, vomltlng,
und nuuseu ure common lf the lndlvlduul lles down for un extended perlod of tlme wlthln 30 mlnutes of tuklng Cllndumycln. In
uddltlon, severe heurt burn cun be expected for up to three duys lf the lndlvlduul does not stuy ln un elevuted posltlon for ut leust
30 mlnutes.
Cllndumycln slde effects.
- dlurrheu;
- dry skln;
- gus;
- ltchlng or burnlng;
- olllness;
- peellng;
- redness or lrrltutlon;
- skln rush;
- upset stomuch;
- vomltlng;
HYDROCORTISONE




CALTRATE

Side/adverse effects
Signs of potential side effects, especially calcium renal calculi or hypercalcemia
ADVERSE REACTIONS FOR CALTRATE PLUS
GI discomfort, hypercalcemia, hypercalciuria.
INDICATIONS FOR CALTRATE PLUS
Calcium supplement.
Who should not take Caltrate 600 Plus Iron Oral?
Check with your physician if you have any of the following:
Conditions:
Diverticular Disease, Arteriosclerosis with Occlusion of the Arteries, Ulcer from Stomach Acid, Ulcerated Colon, Inflammation of the
Lining of the Stomach and Intestines, Kidney Stone, Kidney Disease, Several Blood Transfusions, Sarcoidosis, Increased Activity of
the Parathyroid Gland, Iron Metabolism Disorder causing Increased Iron Storage, Increased Bodily Iron from High Red Blood Cell
Destruction, High Amount of Phosphate in the Blood, High Amount of Calcium in Urine, High Amount of Calcium in the Blood,
Extreme Loss of Body Water, Excessive Amount of Vitamin D in the Body, Hemolytic Anemia
Allergies:
CALCIUM VITAMIN D ANALOGUE (DO NOT USE RETIRED CODE) IRON COMPLEX IRON ANALOGUES




Spironolac-
tone

Octiober

Diuretic

25 mg

Specific
pharmacologic
antagonist of


Aldactone is

Aldactone is
contraindicate
d for patients

GI: Gastric
bleeding,
ulceration,


> Monitor vital
(Aldactone)

Tablet












01, 2009 Tab
OD 6 AM
aldosterone,
acting primarily
through
competitive
binding of
receptors at the
aldosterone-
dependent Na-K
exchange site in
the distal
convoluted
renal tubule. It
causes
increased
amounts of Na
and water to be
excreted, while
K is retained. It
acts both as a
diuretic and as
an
antihypertensiv
e drug by this
mechanism.

indicated to
patients having
hyperaldosteroni
sm, edema,
congestive heart
failure, cirrhosis
of the liver,
nephritic
syndrome,
hypertension,
hypokalemia
with anuria,
acute renal
insufficiency,
significant
impairment of
renal
excretory
function, or
hyperkalemia.

gastritis,
diarrhea,
cramping,
nausea &
vomiting
GU: impotence
CNS:
Confusion,
ataxia,
headache,
drowsiness,
lethargy
Metabolic:
dehydration,hyp
erkalemia,
hyponatremia,
mild acidosis

signs as well as
intake and output
> to prevent
serious
hyperkalemia,
warn patient not to
eat large amounts
of potassium
containign salt
substitutes
> Tell patient to
take drug with
meals